Fuli Li

Analysis of hematologic toxicity profiles following CAR-T cell therapy: a retrospective cohort study

Abstract Background Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed/refractory (R/R) B-cell malignancies, most notably large B-cell lymphoma. However, hematologic toxicity—recently formalized as immune effector cell-associated hematotoxici...